U.S. markets closed
  • S&P Futures

    4,542.00
    +33.50 (+0.74%)
     
  • Dow Futures

    34,255.00
    +253.00 (+0.74%)
     
  • Nasdaq Futures

    15,985.00
    +115.25 (+0.73%)
     
  • Russell 2000 Futures

    2,166.00
    +19.70 (+0.92%)
     
  • Crude Oil

    66.23
    +0.66 (+1.01%)
     
  • Gold

    1,782.20
    -2.10 (-0.12%)
     
  • Silver

    22.47
    +0.13 (+0.56%)
     
  • EUR/USD

    1.1337
    +0.0014 (+0.12%)
     
  • 10-Yr Bond

    1.4340
    -0.0090 (-0.62%)
     
  • Vix

    31.12
    +3.93 (+14.45%)
     
  • GBP/USD

    1.3302
    +0.0025 (+0.18%)
     
  • USD/JPY

    113.0410
    +0.2610 (+0.23%)
     
  • BTC-USD

    56,786.08
    -515.74 (-0.90%)
     
  • CMC Crypto 200

    1,442.85
    -26.23 (-1.79%)
     
  • FTSE 100

    7,168.68
    +109.23 (+1.55%)
     
  • Nikkei 225

    27,750.67
    -184.95 (-0.66%)
     

Capricor Stock Is Moving Higher As Duchenne Dystrophy Cell Therapy Slows Disease Progression By 71%

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Capricor Therapeutics Inc (NASDAQ: CAPR) has announced final data from Phase 2 HOPE-2 trial of CAP-1002 for advanced stages of Duchenne muscular dystrophy (DMD).

  • The trial met its primary efficacy endpoint of mid-level performance of upper limb (mid-PUL v1.2) and various skeletal and cardiac function endpoints.

  • Young men in the advanced stages of DMD experienced improvements in skeletal and cardiac measurements after receiving four doses of CAP-1002 over one year.

  • The results showed that CAP-1002 demonstrated slowed disease progression by 71%.

  • PUL is a tool designed to assess high (shoulder), mid (elbow), and distal (wrist & hand) function.

  • Additional notable endpoints of full PUL v2.0 (p=0.04) and cardiac endpoint of ejection fraction (p=0.002). The final data efficacy analysis shows a change of 3.2 points for full PUL (v1.2) in CAP-1002 versus placebo at 12 months.

  • CAP-1002 was generally safe and well-tolerated.

  • Except for two hypersensitivity reactions early in the clinical trial, which were mitigated with a common pre-medication regimen, the HOPE-2 Data and Safety Monitoring Board (DSMB) identified no serious safety signals.

  • Capricor will host a conference call and webcast today at 8:30 a.m. ET to discuss the final data.

  • Price Action: CAPR stock is up 17.1% at $5.88 during the premarket session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.